Prepaid expenses and other assets |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes and other explanatory information [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaid expenses and other assets |
The Company had the following prepaid expenses at the end of each reporting period:
COSCIENS Biopharma Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2026, and for the three months ended March 31, 2026, and 2025 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||